Non-coding RNA and Drug Resistance in Head and Neck Cancer

Overview

Journal Cancer Drug Resist

Date 2024 Oct 15

PMID 39403599

Authors

Yulong Zhang

Yingming Peng

Bingqin Lin

Shuai Yang

Feiqiang Deng

Xuan Yang

An Li

Wanyi Xia

Chenxi Gao

Shaona Lei

Wei Liao

Qi Zeng

Affiliations

Soon will be listed here.

Abstract

Head and neck cancer (HNC) is ranked as the sixth most common malignant tumor, and the overall survival rate with current treatment options remains concerning, primarily due to drug resistance that develops following antitumor therapy. Recent studies indicate that non-coding RNAs play a crucial role in drug resistance among HNC patients. This article systematically reviews the current research landscape, explores novel targets and treatment strategies related to non-coding RNAs and HNC resistance, raises some unresolved issues, and discusses five promising research directions in this field: ferroptosis, nanomedicine, exosomes, proteolysis-targeting chimeras (PROTACs), and artificial intelligence. We hope that our work will contribute to advancing research on overcoming HNC resistance through the regulation of non-coding RNAs.

Citing Articles

Synthesis and Evaluation of Boron-Containing Heterocyclic Compounds with Antimicrobial and Anticancer Activities.

Prates J, de Matos Silva S, Medina-Alarcon K, Dos Santos K, Belizario J, Lopes J Molecules. 2025; 30(5).

PMID: 40076340 PMC: 11901438. DOI: 10.3390/molecules30051117.

References

Liu X, Guo Q, Gao G, Cao Z, Guan Z, Jia B . Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. J Nanobiotechnology. 2023; 21(1):45. PMC: 9906870. DOI: 10.1186/s12951-023-01801-w. View

Xue F, Cheng Y, Xu L, Tian C, Jiao H, Wang R . LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer. Aging (Albany NY). 2020; 12(14):14174-14188. PMC: 7425502. DOI: 10.18632/aging.103427. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Jing X, Xie M, Ding K, Xu T, Fang Y, Ma P . Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53. Clin Transl Med. 2022; 12(5):e780. PMC: 9076018. DOI: 10.1002/ctm2.780. View

Debnath J, Gammoh N, Ryan K . Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023; 24(8):560-575. PMC: 9980873. DOI: 10.1038/s41580-023-00585-z. View

Tang J, Wang X, Xiao D, Liu S, Tao Y . The chromatin-associated RNAs in gene regulation and cancer. Mol Cancer. 2023; 22(1):27. PMC: 9903551. DOI: 10.1186/s12943-023-01724-y. View

Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y . Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol Cancer. 2022; 21(1):99. PMC: 8996410. DOI: 10.1186/s12943-021-01434-3. View

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

Yuan L, Li S, Chen Q, Xia T, Luo D, Li L . EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 2022; 29(8):1513-1527. PMC: 9346003. DOI: 10.1038/s41418-022-00939-8. View

10.

Shin D, Kim E, Lee J, Roh J . Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018; 129:454-462. DOI: 10.1016/j.freeradbiomed.2018.10.426. View

11.

Huang C, Zhou Y, Feng X, Wang J, Li Y, Yao X . Delivery of Engineered Primary Tumor-Derived Exosomes Effectively Suppressed the Colorectal Cancer Chemoresistance and Liver Metastasis. ACS Nano. 2023; 17(11):10313-10326. DOI: 10.1021/acsnano.3c00668. View

12.

Kabekkodu S, Shukla V, Varghese V, D Souza J, Chakrabarty S, Satyamoorthy K . Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc. 2018; 93(4):1955-1986. DOI: 10.1111/brv.12428. View

13.

Shaw P, Raymond G, Senthilnathan R, Kumarasamy C, Baxi S, Suresh D . Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol. Genes (Basel). 2021; 12(12). PMC: 8702026. DOI: 10.3390/genes12122029. View

14.

Zhang L, Meng X, Zhu X, Yang D, Chen R, Jiang Y . Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications. Mol Cancer. 2019; 18(1):102. PMC: 6535863. DOI: 10.1186/s12943-019-1021-3. View

15.

Meng X, Lou Q, Yang W, Wang Y, Chen R, Wang L . The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond). 2021; 41(10):981-1006. PMC: 8504146. DOI: 10.1002/cac2.12194. View

16.

Yu Z, Tang H, Chen S, Xie Y, Shi L, Xia S . Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy. Drug Resist Updat. 2023; 67:100915. DOI: 10.1016/j.drup.2022.100915. View

17.

Zhang J, Ye Z, Chakraborty P, Luo Z, Culpepper J, Aslam M . Microsomal glutathione transferase 1 controls metastasis and therapeutic response in melanoma. Pharmacol Res. 2023; 196:106899. PMC: 10623471. DOI: 10.1016/j.phrs.2023.106899. View

18.

Wang Z, Yang L, Wu P, Li X, Tang Y, Ou X . The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022; 21(1):29. PMC: 8785480. DOI: 10.1186/s12943-022-01498-9. View

19.

Cui J, Wang H, Zhang X, Sun X, Zhang J, Ma J . Exosomal miR-200c suppresses chemoresistance of docetaxel in tongue squamous cell carcinoma by suppressing TUBB3 and PPP2R1B. Aging (Albany NY). 2020; 12(8):6756-6773. PMC: 7202518. DOI: 10.18632/aging.103036. View

20.

Wu J, Li S, Zhang P . Tumor-derived exosomes: immune properties and clinical application in lung cancer. Cancer Drug Resist. 2022; 5(1):102-113. PMC: 8992595. DOI: 10.20517/cdr.2021.99. View